NASDAQ: NMRANeumora Therapeutics Inc Stock
$9.09-0.37 (-3.91%)
Updated Apr 30, 2024
NMRA Price
$9.09
Fair Value Price
N/A
Market Cap
$1.44B
52 Week Low
$8.82
52 Week High
$21.00
P/E
-2.5x
P/B
3.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$235.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$163M
Beta
1.42
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NMRA Overview
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NMRA is good value based on its book value relative to its share price (3.08x), compared to the US Biotechnology industry average (5.89x)
P/B vs Industry Valuation
NMRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NMRA due diligence checks available for Premium users.
Be the first to know about important NMRA news, forecast changes, insider trades & much more!
NMRA News
Valuation
NMRA fair value
Fair Value of NMRA stock based on Discounted Cash Flow (DCF)
Price
$9.09
Fair Value
$1.53
Overvalued by
494.07%
NMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.5x
Industry
14.91x
Market
40.82x
NMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.08x
Industry
5.89x
NMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$108.7M
Profit Margin
0%
NMRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$496.2M
Liabilities
$27.1M
Debt to equity
0.06
NMRA's short-term assets ($478.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NMRA's short-term assets ($478.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$51.4M
Investing
$13.7M
Financing
-$481.0k
NMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NMRA vs Biotech Stocks
Neumora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.